---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-26-000041"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2026-09-11T20:08:25+00:00"
generated_at: "2026-09-11T20:09:04.909789+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nautilus enters new $125M ATM sales agreement with TD Cowen; terminates prior unused agreement

## Summary
- Entered ATM sales agreement with TD Cowen to sell up to $125M of common stock, with commission up to 3% of gross proceeds.
- Prior ATM agreement dated Feb 28, 2024 mutually terminated; no shares had been sold under it.
- Sales will occur via Rule 415 at-the-market offering under new S-3 shelf registration statement filed Sept 11, 2026.
- Company not obligated to sell any shares and may suspend sales at any time.

## SEC filing metadata
- accession: 0001808805-26-000041
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2026-09-11T20:08:25+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880526000041/0001808805-26-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880526000041/naut-20260911.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-26-000041
- JSON: https://secwatch.observer/filing/0001808805-26-000041.json
- Plain text: https://secwatch.observer/filing/0001808805-26-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.